- Published on: December 7, 2021
- 11:47
Havana, Dec 7 (Prensa Latina) One year has passed since the beginning of phase I and II of clinical trial with the then vaccine candidate Abdala, the results of which allowed its validation for emergency use to become the first immunizer against Covid-19 in Latin America.
